10 November 2020 Patient access schemes (PAS) – process revision From November 2020 our process has changed to align the arrangements for Patient Access Schemes (PAS) across all submissions.
9 November 2020 November 2020 decisions news release Advice on eight new medicines published Advice on eight new medicines for use in conditions including breast cancer, lung cancer and osteoporosis has today (Monday 9 October) been published by the Scottish Medicines Consortium.
3 November 2020 Blogs highlight SMC's successful move to virtual committee meetings Transition to virtual meetings a success
12 October 2020 October 2020 decisions news release SMC publishes advice on nine new medicines The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 5 October) published advice on nine new medicines.
15 September 2020 SMC plays key role in helping to secure access to COVID-19 treatments The Scottish Medicines Consortium is part of a UK-wide multi-agency initiative to secure access to potential new treatments for COVID-19 to NHS patients quickly and safely.
7 September 2020 September 2020 decisions news release SMC accepts fourteen new medicines for use by NHSScotland The Scottish Medicines Consortium, (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 7 September) published advice accepting fourteen new medicines.
10 August 2020 August 2020 decisions news release SMC accepts breast cancer medicine for use by NHSScotland The Scottish Medicines Consortium, (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 10 August) published advice accepting neratinib (Nerlynx) for the treatment of breast cancer.
7 July 2020 SMC remobilisation Following the suspension of our Scottish Medicines Consortium (SMC), New Drugs Committee (NDC) and Patient and Clinician Engagement (PACE) meetings during the early stages of the COVID-19 pandemic, we are pleased to announce that we will be resuming meetings in the near future.
